David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion.
Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
Galapagos has taken up its option to co-promote filgotinib with Gilead in certain European nations, but Gilead will be free to acquire its partner in two weeks.
The five-year pact puts CRT in charge of discovering drugs that affect protein assembly and taking them through phase 1.
Scientists at the University of Michigan Comprehensive Cancer Center believe they've discovered a novel gene that can be inhibited with antisense…
Teva's restructuring plan will include the closure or divestiture of R&D facilities, as well as a "thorough review" of its R&D programs.
Kyn Therapeutics has debuted after almost two years of gestation at Atlas Venture with three immuno-metabolism platforms and $49 million in funding.
The 144 patients who received Ampion in the latest trial outperformed tthe control cohort in terms of the responder criteria,
In this week's EuroBiotech Report, Gilead backs Hookipa’s $60 million round, Erytech hit by cancer failure, Ex-Dezima execs plot NASH trial and more.
Argenx raises $231 million after a data boost, Cellectis climbs on CAR-T results and ADCT posts a cancer drug update.